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Abstract 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), persists within infected macrophages for long 
periods of time in a metabolically inactive but reversible state known as dormancy. Since the majority of adult pulmonary TB is 
caused by the reactivation of persistent Mtb, novel vaccines to protect against disease reactivation and novel biomarkers to 
provide the basis of new diagnosis of latent infection are urgently needed. To meet this demand, we assessed the immunogenicity 
of 32 latency-associated proteins in DNA-vaccinated mice. By using a Helios gene gun, BALB/c and C57BL/6 mice were 
vaccinated with plasmids carrying DNAs for latency-associated antigens encoded by the DosR regulon. Of the 32 antigens tested, 
12 induced antigen-specific T-cell responses in vaccinated BALB/c mice and 9 induced responses in C57BL/6 mice. Five 
antigens (Rv1998c, Rv2031c, Rv2032, Rv2623, and Rv3132c) induced T-cell responses in both mice strains. In addition, at least 
12 and 3 antigens induced antigen-specific antibody production in vaccinated BALB/c and C57BL/6 mice, respectively. Of these, 
3 antigens (Rv2029c, Rv2626c, and Rv3132c) induced strong antibody production in both mice strains. These results might be 
applicable for the future development of a novel vaccine and biomarkers for latent TB infection, although further analyses in 
human blood samples are necessary. 
 
© 2010 Published by Elsevier Ltd. 
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1. Introduction 
Tuberculosis (TB) has plagued humans for thousands of years, and more than 2 billion people (equal to 
approximately one-third of the world’s population) are currently infected with the causative agent Mycobacterium 
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tuberculosis (Mtb) (1). However, less than 10% of the infected individuals actually develop active diseases 
(approximately 9.4 million new incidences in 2008) (1), and Mtb infection remains latent with no overt clinical 
symptoms throughout the life in more than 90% of infected individuals. Such statistical evidence indicates the 
efficacy of naturally induced immune responses, at least in the resistant population. The risk of developing active 
TB is increased in immunocompromised individuals, especially in HIV-positive people (1). While infected 
immunocompetent individuals mount a cell-mediated immune response against Mtb, most of them do not achieve 
complete eradication of the microbe (25). Consequently, Mtb bacilli can persist within the human body, especially 
in the lung, for long periods of time in a metabolically inactive but reversible state known as dormancy (25). The 
major cause of adult pulmonary TB, the most prevalent form of the disease, is reactivation of such persistent Mtb 
bacilli (6), although the differences between resistant and susceptible populations to TB reactivation are not fully 
understood. 
The current TB vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) was developed nearly 90 years 
ago and is the most widely used vaccine worldwide (710), although it has been reported to exhibit variable 
protective efficacy (11). This vaccine efficiently protects against severe disseminated TB (miliary TB) in newborns 
and young children, but fails to prevent adult pulmonary TB. Accordingly, BCG has virtually no effect on TB 
transmission in the adult population (12). The ineffectiveness of BCG to protect against the highly prevalent TB in 
adults has stimulated many efforts to establish more effective vaccine protocols. In general, these attempts can be 
divided into two categories, i.e., (i) subunit vaccines composed of one or a few antigens and (ii) recombinant viable 
vaccines superior to BCG (7, 8). Considering the complementary strength of both types of vaccines, a heterologous 
prime-boost regimen comprising a prime with a viable vaccine superior to BCG and a boost with a subunit vaccine 
seems to be the most promising combination (7, 8). 
After Mtb enters the lungs by inhalation, the bacterial cell is engulfed by alveolar macrophages and probably 
dendritic cells (DCs); however, Mtb can escape from digestion by these phagocytic cells (13). Consequently, 
infected macrophages and DCs serve as mobile reservoirs that transport the bacteria, eventually to draining lymph 
nodes, where presentation of mycobacterial antigens to T cells occurs (25). As a regional immune response, 
activated antigen-specific T cells induce the formation of a granuloma around infected macrophages, primarily 
composed of monocyte-derived macrophages, CD4+ T cells, and CD8+ T cells (14). In the granuloma, surrounding T 
cells activate macrophages through the production of Th1 cytokines such as interferon (IFN)-J and tumor necrosis 
factor (TNF)-D (14), and IFN-J augments the capacity to control Mtb in macrophages (15, 16). The granuloma can 
persist for years and deprive the arrested Mtb of oxygen and nutrients; therefore, the bacterial cells survive probably 
in a state of dormancy (17-20). Recent DNA microarray analysis revealed upregulation of the DosR regulon, which 
comprises 48 genes (including the heat shock protein (hsp) X/D-crystallin), in Mtb during its dormancy state (19, 
20). Therefore, in this study, we assessed the immunogenicity of these antigens in DNA-vaccinated mice. We 
anticipate that our results can provide useful information not only for the establishment of novel vaccines to control 
TB reactivation but also for the development of biomarkers for new diagnosis of latent Mtb infection. 
2. Materials and Methods 
2.1. Preparation of DNAs 
DNAs encoding the DosR regulon proteins (20) were amplified by PCR using genomic DNAs of Mtb H37Rv or 
BCG as templates. Primers were designed according to the genetic information obtained from the TubercuList 
(http://genolist.pasteur.fr/TubercuList/). Appropriate restriction sites were introduced at the 5ƍ and 3ƍ ends of the 
DNAs by PCR, and the PCR products were digested and ligated into the corresponding restriction sites of pCI 
(Promega, Madison, WI, USA) and pET-28b(+) (Novagen/Merck, Darmstadt, Germany) vectors for DNA vaccine 
and recombinant protein preparation, respectively. Plasmids were purified using commercially available Plasmid 
Purification Kits (Qiagen GmbH, Hilden, Germany), according to the manufacturer’s instructions. The nucleotide 
sequences were confirmed by automated DNA sequencing (ABI PRISM 310 Genetic Analyzer, Applied 
Biosystems, Foster City, CA, USA) using a dye primer cycle sequencing kit (Applied Biosystems). 
 
2.2. Preparation of recombinant proteins 
Escherichia coli BL21(DE3) competent cells (Novagen/Merck) were transformed with pET-28(+) vectors 
containing the DNAs for the DosR regulon proteins. Proteins were induced with isopropyl E-D(-)-
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thiogalactopyranoside (IPTG, Wako Pure Chemical Industries, Ltd., Osaka, Japan). Proteins were extracted from the 
bacterial cells with 7 M urea (Wako Pure Chemical Industries, Ltd.) and purified by Ni2+-nitrilotriacetic acid (Ni-
NTA) agarose (Qiagen) according to the manufacturer’s instructions. 
 
2.3. Mice and vaccination 
Female BALB/c and C57BL/6 mice (8 and 12 weeks of age) were purchased from Japan SLC (Hamamatsu, 
Japan) and maintained in the animal facility of Hamamatsu University School of Medicine under specific pathogen-
free conditions. All animal experiments were performed according to the Guidelines for Animal Experimentation 
issued by the Hamamatsu University School of Medicine. Mice were vaccinated with plasmids using a Helios gene 
gun system (Bio-Rad Laboratories, Hercules, CA, USA) three times at 2-week intervals as described previously 
(21). 
 
2.4. Enzyme-linked immunosorbent assay (ELISA) for IFN-J 
Two weeks after the last vaccination, spleen cells from the vaccinated and non-vaccinated control mice were 
cultured in a 96-well plate (1 × 106 cells/0.2 ml/well) in the presence or absence of corresponding antigens for 2 
days. IFN-J concentration of the culture supernatants was determined by a sandwich ELISA as described previously 
(21). 
 
2.5. Serum preparation and antibody titration 
Two weeks after the last vaccination, sera from the vaccinated mice were prepared as described (22). Pre-
vaccinated sera from the corresponding vaccinated mice were also prepared. Indirect ELISA to detect antigen-
specific antibodies in the sera from mice (both pre- and post-vaccination) was conducted as described (23), with 
slight modifications, using peroxidase-labeled goat anti-mouse IgG+A+M (H+L) antibody (Zymed/Invitrogen, 
Carlsbad, CA, USA) and 3,3ƍ,5,5ƍ-tetramethylbenzidine (TMB) (BioFX Laboratories, Owings Mills, MD, USA). 
 
Fig. 1. Experimental design for the 
measurement of T-cell responses against 
latency-associated antigens. DNAs for 
DosR regulon proteins were obtained by 
PCR using the genomic DNA of Mtb 
H37Rv or BCG as templates and were 
cloned into pCI and pET-28b(+) vectors for 
DNA vaccine and recombinant protein 
preparation, respectively. By using a Helios 
gene gun, BALB/c and C57BL/6 mice were 
vaccinated three times at 2-week intervals 
with the plasmids encoding antigen DNA. 
Two weeks after the last vaccination, spleen 
cells from the vaccinated and non-
vaccinated mice were stimulated with 
corresponding antigen proteins prepared by 
the bacterial pET system, and the 
production of IFN-J was tested by ELISA. 
 
3. Results and Discussion 
T cell responses against DosR regulon-encoded antigens were measured as illustrated in Fig. 1. The results of 
these experiments are shown in Fig. 2 and Table 1. Of the 32 DosR regulon-encoded antigens tested, 12 induced 
antigen-specific T-cell responses in vaccinated BALB/c mice and 9 induced responses in C57BL/6 mice. Of these 
antigens that induced responses, 5 antigens (Rv1998c, Rv2031c, Rv2032, Rv2623, and Rv3132c) induced T-cell 
responses in both mice strains, although the intensity of their responses varied. The antigen Rv0079 also showed a 
strong immunogenicity in a single BALB/c mouse and in 2 C57BL/6 mice, but failed to induce a T-cell response in 
the BALB/c mouse. In addition, Rv2628 induced strong T-cell responses in BALB/c mice only. In contrast, 
Rv2624c induced intermediate T-cell responses in C57BL/6 mice, while its immunogenicity was relatively low in 
BALB/c mice. 




Fig. 2. T-cell responses against DosR regulon proteins. By using a 
Helios gene gun, BALB/c or C57BL/6 mice were vaccinated with the 
plasmids encoding the corresponding antigen DNA. Spleen cells (1 u 
105 cells) from the vaccinated mice were cultured for 48 h in the 
presence of corresponding antigens, and the production of IFN-J was 
then tested by a sandwich ELISA. Closed diamonds and open circles 
represent the individual results of immunized and naïve mice, 
respectively. Dotted vertical lines represent the thresholds between 
positive and negative. 
Fig. 3. Antibody production against DosR regulon proteins. Sera 
from mice (both pre- and post-vaccination) were diluted 100 times, 
and the titers for antigen-specific antibody were measured by ELISA. 
Closed diamonds and open circles represent the individual results of 























Fig. 4. Titration analysis of sera with high titers for antigen-specific antibody. Sera from mice (both pre- and post-vaccination) were serially 
diluted, and the titers for antigen-specific antibody were measured by ELISA. Closed diamonds and open circles represent the individual results 
of vaccinated and pre-vaccinated mice, respectively. 
 









Antibody production against DosR regulon-encoded antigens in DNA-vaccinated mice was also examined, 
although some results have yet to be obtained. As shown in Fig. 3 and Table 1, at least 12 DosR regulon-encoded 
antigens induced antigen-specific antibody production in vaccinated BALB/c and 3 antigens induced antibody 
production in C57BL/6 mice. Of the antigens that produced antibody, 3 antigens (Rv2029c, Rv2626c, and Rv3132c) 
induced strong antibody production in both mice strains (Figs. 3 and 4). Rv0081 and Rv2624c also induced strong 
antibody production in BALB/c mice, while their effects in C57BL/6 mice have not been tested. 
Table 1 summarizes the present study results and shows the results of a previous report for comparison (24). Both 
studies showed that Rv2031c (hsp X/D-crystallin) effectively induced antigen-specific cellular and humoral immune 
responses in both mice strains, although we have not assessed the humoral response in C57BL/6 mice. In addition to 
Rv2031c, our present study also showed that Rv3132c (desV) induced antigen-specific cellular and humoral 
immune responses in both mice strains, although its immunogenicity in T-cell responses seemed relatively low. 
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Rv2032 also showed a similar immunogenicity between the two studies, i.e., only T-cell responses were induced in 
both BALB/c and C57BL/6 mice. On the other hand, while Roupie et al. showed high and intermediate IFN-J 
production by spleen cells from vaccinated C57BL/6 mice in response to Rv2626c and Rv2628, respectively, we did 
not detect T-cell responses against these antigens in the same strain. The discordance may stem from the differences 
in DNA-vaccine constructs, vaccination formula, and/or assay conditions, but the actual cause(s) has not been 
clarified. Some differences were also observed across studies in the results for the antigens showing low 
immunogenicity. 
IFN-J-secreting CD4+ T cells, also known as Th1 cells, are important mediators of TB protection (15, 16). 
Attempts to induce TB antigen-specific Th1 cells have been the dominant theme of most TB vaccine development 
studies (7, 8). In addition, accumulating evidence shows that CD8+ cytotoxic T lymphocytes (CTLs) also contribute 
to disease resistance (25). Therefore, identification of highly immunogenic antigens recognized by T cells is a 
particularly important step in the development of TB vaccines. However, since T-cell responses are induced in an 
MHC-restricted manner (25, 26), T-cell antigens found in murine systems are not necessarily applicable for human 
vaccines. In addition, HLA heterogeneity should also be considered during vaccine development. Recent studies 
revealed that the immunogenicity of latency-associated antigens varies not only between individuals of European 
and African descent but also among African people (27, 28). MHC class II binding motifs, however, are not as 
tightly restricted as those of MHC class I (29). Promiscuous peptides binding to different MHC class II molecules 
have been reported (30). Of note, some promiscuous peptides are associated with both mouse and human MHC class 
II molecules (31, 32). We are currently attempting to identify T-cell epitopes on the antigens found immunogenic in 
this study that are shared by both mouse and human MHC class II molecules. 
In addition to the establishment of vaccine protocols and therapeutic regimens against TB, another important 
issue in TB management is the development of biomarkers applicable for monitoring clinical trials and for making 
more rapid and accurate diagnoses and prognoses of the outcome of infections and drug treatments (33, 34). For TB 
diagnosis, a tuberculin skin test (TST) is still used today, although this test has many major disadvantages, including 
poor specificity (false-positive tests caused by prior vaccination or previous exposure to environmental 
mycobacteria) and poor sensitivity (false-negative tests in children and immunocompromised individuals) (34). 
Newly established IFN-J release assays using specific antigens of ESAT-6 and CFP-10, such as the QuantiFERON-
TB Gold test (Cellestis Limited, Carnegie, Victoria, Australia) and the T-SPOT.TB test (Oxford Immunotech 
Limited, Abingdon, UK), can differentiate infection from BCG vaccination, but these methods still have some 
limitations (35). 
We are hopeful that the immune responses against latency-associated antigens observed in this study can 
ultimately be used as biomarkers for the diagnosis of latent infection of Mtb. To this end, we have initiated a few 
human studies to measure the immunogenicity of latency-associated antigens. Since antibody-based assays are 
generally easier and cheaper than T cell-based assays, the former may be particularly suitable for the measurement 
of biomarkers, especially in developing countries. In this regard, we have found 3 strong B-cell antigens (Rv2029c, 
Rv2626c, and Rv3132c) that are commonly immunogenic in both strains tested. Rv0079, Rv0080, Rv1738, 
Rv2626c, and Rv3127 potentially have similar characteristics. Therefore, it would be interesting to verify whether 
the antibody production against these antigens in humans can be used as the biomarkers for the diagnosis of latent 
infections and/or active diseases. Such a study is currently in progress. 
In conclusion, in this study we assessed the immunogenicity of latency-associated antigens in DNA-vaccinated 
mice and found that of 32 antigens, 12 and 9 antigens induced antigen-specific T-cell responses in vaccinated 
BALB/c and C57BL/6 mice, respectively. In addition, we found that at least 12 antigens induced antigen-specific 
antibody production in vaccinated BALB/c and 3 induced production in C57BL/6 mice. Our next aims are to 
identify the epitopes on these T-cell antigens and to assess the immune responses against them by using human 
blood samples. 
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